CELEX: 62017CN0443
Language: en
Date: 2017-07-24 00:00:00
Title: Case C-443/17: Reference for a preliminary ruling from High Court of Justice (Chancery Division) (United Kingdom) made on 24 July 2017 — Abraxis Bioscience LLC v Comptroller General of Patents

18.9.2017   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 309/30
            
         Reference for a preliminary ruling from High Court of Justice (Chancery Division) (United Kingdom) made on 24 July 2017 — Abraxis Bioscience LLC v Comptroller General of Patents
   (Case C-443/17)
   (2017/C 309/41)
   Language of the case: English
   
      Referring court
   
   High Court of Justice (Chancery Division)
   
      Parties to the main proceedings
   
   
      Applicant: Abraxis Bioscience LLC
   
      Defendant: Comptroller General of Patents
   
      Question referred
   
   Is Article 3(d) of the SPC Regulation (1) to be interpreted as permitting the grant of an SPC where the marketing authorisation referred to in Article 3(b) is the first authorisation within the scope of the basic patent to place the product on the market as a medicinal product and where the product is a new formulation of an old active ingredient?
   
      (1)  Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (OJ L 152, p. 1)